Each Film Coated Tablet contains Atorvastatin calcium trihydrate 10.82mg Equivalent to Atorvastatin 10mg + Ezetimibe 10mg.
Each Film Coated Tablet contains Atorvastatin calcium trihydrate 21.64mg equivalent to Atorvastatin 20mg + Ezetimibe 10mg.
a- Primary Hyperlipidemia:
Atrozemb® is indicated for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol
(LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and to
increase high-density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial and non-familial)
hyperlipidemia or mixed hyperlipidemia.
b- Homozygous Familial Hypercholesterolemia (HoFH):
Atrozemb® is indicated for the reduction of elevated total-C and LDL-C in patients with homozygous familial
hypercholesterolemia, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are
Mechanism of Action
Competitive inhibition of HMG CoA reductase, the rate-limiting step in cholesterol synthesis.
Selectively inhibits absorption of dietary and biliary cholesterol in the small intestine.
Dosage and Method of Usage
One film coated tablet to be taken orally once daily
Package and Storage
All Rights Reserved Liptis Pharmaceuticals 2021